BioPhi
Humanize and assess antibody variable domains.
Results
Loading starting example…
Method & evidence
Generate humanized variants or measure exact OAS repertoire 9-mer prevalence, then inspect the sequence-level evidence before selecting candidates.
Scope & limitations
- OASis uses the official OASis_9mers_v1 database and exact BioPhi denominator semantics; it does not substitute a germline similarity or Sapiens score.
Interpreting results
- Sequence identity reports how much of the parental variable domain is retained; a higher value means fewer proposed substitutions.
- Compare parental and humanized assigned scores residue by residue. They are model scores, not direct measurements of immunogenicity.
- Use numbered mutations and framework/CDR labels to identify changes that need structural, binding, or assay review.
- OASis identity is the fraction of overlapping 9-mers meeting the selected human-subject prevalence threshold; it is a repertoire-prevalence proxy, not a direct immunogenicity probability.
- Use the peptide and residue maps to localize low-prevalence sequence segments before deciding whether a substitution is biologically acceptable.
References
Input requirements & outputs
Input checks
- 40–180 unambiguous amino acids per variable domain
- Heavy, kappa, or lambda chain type supplied per row
- Up to 16 sequences in one analysis
Expected results
- Parental-to-variant residue map — Review numbered substitutions by framework or CDR region.
- Humanization score comparison — Compare assigned residue scores before and after humanization.
- Germline, identity, and repertoire summary — For humanization, inspect V/J assignments and mutations; for OASis, inspect identity, percentile, and human/non-human 9-mer counts.
- Low-prevalence peptide map — Locate each low-prevalence overlapping 9-mer and see which numbered residues it affects.
